BRKR:NSD-Bruker Corporation (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 58.51

Change

+0.46 (+0.79)%

Market Cap

USD 9.04B

Volume

1.33M

Analyst Target

USD 47.92
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.44 (-0.61%)

USD 29.04B
PODD Insulet Corporation

-1.79 (-0.77%)

USD 16.66B
MASI Masimo Corporation

+1.84 (+1.30%)

USD 7.53B
TMDX TransMedics Group Inc

-6.58 (-7.44%)

USD 4.17B
AXNX Axonics Modulation Technologie..

+0.05 (+0.07%)

USD 3.59B
PRCT Procept Biorobotics Corp

-3.66 (-3.79%)

USD 3.50B
LIVN LivaNova PLC

-1.63 (-3.08%)

USD 2.90B
QDEL Quidel Corporation

+0.62 (+1.62%)

USD 2.67B
NARI Inari Medical Inc

-2.08 (-4.23%)

USD 2.57B
IRTC iRhythm Technologies Inc

-1.23 (-1.60%)

USD 2.36B

ETFs Containing BRKR

TYNE 12.61 % 0.00 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

-0.20 (0%)

USD 0.39B
HLTH:AU VanEck Global Healthcare .. 0.00 % 0.00 %

+0.09 (+0%)

USD 0.06B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.37% 38% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.37% 38% F 30% F
Trailing 12 Months  
Capital Gain 2.63% 38% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.63% 38% F 38% F
Trailing 5 Years  
Capital Gain 16.79% 65% D 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.79% 65% D 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 17.81% 60% D- 73% C
Dividend Return 18.11% 60% D- 72% C
Total Return 0.29% 50% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 36.56% 74% C 51% F
Risk Adjusted Return 49.52% 93% A 78% C+
Market Capitalization 9.04B 98% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector